MARKET

BDTX

BDTX

Black Diamond Therapeutics, Inc.
NASDAQ
1.980
+0.030
+1.54%
After Hours: 1.980 0 0.00% 19:34 08/10 EDT
OPEN
1.950
PREV CLOSE
1.950
HIGH
2.020
LOW
1.930
VOLUME
665.00K
TURNOVER
--
52 WEEK HIGH
4.940
52 WEEK LOW
1.600
MARKET CAP
113.76M
P/E (TTM)
-2.6121
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BDTX last week (0803-0807)?
Weekly Report · 21h ago
Raymond James keeps Outperform rating on Black Diamond Therapeutics after Q2
TipRanks · 4d ago
Black Diamond Therapeutics setup ‘attractive,’ says Jefferies
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT)
TipRanks · 4d ago
Black Diamond Therapeutics GAAP EPS of -$0.17 beats by $0.03
Seeking Alpha · 5d ago
Black Diamond Therapeutic Q2 EPS $(0.17) Beats $(0.19) Estimate
Benzinga · 5d ago
Black Diamond Therapeutics reports Q2 EPS (17c), consensus (20c)
TipRanks · 5d ago
Press Release: Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 5d ago
More
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Webull offers Black Diamond Therapeutics Inc stock information, including NASDAQ: BDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BDTX stock methods without spending real money on the virtual paper trading platform.